Category: Clinical Breakthroughs
-
Young at Heart
Heart health at all ages is central to the Women’s Cardiovascular Health Program at Northwestern Medicine’s Bluhm Cardiovascular Institute.
-
New Drug Clears Psoriasis in Clinical Trials
Patients with psoriasis saw their disease completely or almost completely cleared with a new drug called ixekizumab in three recent clinical trials led by a Northwestern Medicine investigator
-
Targeting Immune Cell Trafficking in Colon Disease
A new drug safely and effectively treats patients with ulcerative colitis, according to a recent study co-authored by Northwestern Medicine investigator Stephen Hanauer, MD.
-
Data Science Transforming Biomedical Research at Feinberg
New data science initiatives propel Feinberg to “the future of medicine” and individualized patient care.
-
Comparing Foods Could Get Easier With NUCATS Funding
A Northwestern research team has created a database of 17,000 foods and beverages for an app that will help consumers see nutrition information.
-
Evaluating an Alternative to Open-Heart Surgery
A minimally invasive procedure to repair aortic stenosis may be preferable to open-heart surgery when treating patients at intermediate risk of surgical mortality, according to recent research.
-
Residents Investigate Regulation of Women’s Health Devices
Some high-risk medical devices used in obstetrics and gynecology were approved by the FDA based on flawed data, according to a recent study conducted by Northwestern Medicine residents.
-
Linking Mothers’ Obesity-Related Genes to Babies’ Birth Weight
A study co-authored by Northwestern Medicine scientists suggests that genetic factors associated with elevated body mass index and higher blood sugar levels in mothers cause babies to be born heavier.
-
Testing Diabetes Drug Dosage
Northwestern Medicine physicians participated in a clinical trial to investigate the safety and efficacy of a drug for weight management in overweight or obese adults with type 2 diabetes.
-
Investigating Kidney Cancer Therapies
Two drugs known to improve survival for patients with metastatic renal cell carcinoma do not reduce the risk of cancer recurrence when administered after surgery, according to a recent clinical trial.
